Skip to content
10-Q

Quarterly Report

Tobira Therapeutics, Inc.

0001564590-15-010335

← back to feed
Filed
Nov 10, 2015 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2015 · Nov 6, 2015 18.81M sh
Stock Issued Q3 2015 · Sep 30, 2015 1.14M sh
Capex Q3 2015 · Sep 30, 2015 $31K
Capex restated Q3 2015 · Sep 30, 2014 $130K
Long Term Debt Q3 2015 · Sep 30, 2015 $15.01M
Long Term Debt Q3 2015 · Dec 31, 2014 $14.79M
Cash And Equivalents Q3 2015 · Sep 30, 2015 $68.62M
Cash And Equivalents Q3 2015 · Dec 31, 2014 $6.18M
Cash And Equivalents restated Q3 2015 · Sep 30, 2014 $11.81M
Cash And Equivalents restated Q3 2015 · Dec 31, 2013 $4.09M
Stockholders Equity Q3 2015 · Sep 30, 2015 $51.33M
Stockholders Equity Q3 2015 · Dec 31, 2014 −$109.38M
Current Liabilities Q3 2015 · Sep 30, 2015 $5.26M
Current Liabilities Q3 2015 · Dec 31, 2014 $38.24M
Total Liabilities Q3 2015 · Sep 30, 2015 $20.49M
Total Liabilities Q3 2015 · Dec 31, 2014 $55.75M
Current Assets Q3 2015 · Sep 30, 2015 $69.51M
Current Assets Q3 2015 · Dec 31, 2014 $7.19M
Total Assets Q3 2015 · Sep 30, 2015 $71.82M
Total Assets Q3 2015 · Dec 31, 2014 $8.35M
Sga Expense Q3 2015 · Sep 30, 2015 $2.83M
Sga Expense Q3 2015 · Sep 30, 2015 $8.1M
Sga Expense restated Q3 2015 · Sep 30, 2014 $12K
Sga Expense restated Q3 2015 · Sep 30, 2014 $2.75M
Rd Expense Q3 2015 · Sep 30, 2015 $6.09M
Rd Expense Q3 2015 · Sep 30, 2015 $18.38M
Rd Expense restated Q3 2015 · Sep 30, 2014 $3.51M
Rd Expense restated Q3 2015 · Sep 30, 2014 $8.27M
Net Income Q3 2015 · Sep 30, 2015 −$22.21M
Net Income Q3 2015 · Sep 30, 2015 −$40.23M
Net Income restated Q3 2015 · Sep 30, 2014 −$2.94M
Net Income restated Q3 2015 · Sep 30, 2014 −$13.69M
Operating Income Q3 2015 · Sep 30, 2015 −$26.23M
Operating Income Q3 2015 · Sep 30, 2015 −$43.79M
Operating Income restated Q3 2015 · Sep 30, 2014 −$3.52M
Operating Income restated Q3 2015 · Sep 30, 2014 −$11.03M